Assembly Biosciences (ASMB) Cash & Equivalents Growth (1y) (2011 - 2026)
Powered by 
Analysis
Assembly Biosciences (ASMB) Cash & Equivalents Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 23.56% |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 23.05% |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 71.81% |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 34.71% |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 84.98% |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 53.39% |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 28.50% |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -57.58% |
| 10 | Assembly Biosciences | 683.92 Mn | 363.56 Mn | - | 34.49% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 34.49% |
| Mar 31, 2026 | 32.92% |
| Dec 31, 2025 | 52.44% |
| Sep 30, 2025 | -20.80% |
| Jun 30, 2025 | 24.98% |
| Mar 31, 2025 | 24.88% |
| Dec 31, 2024 | 93.26% |
| Sep 30, 2024 | 6.74% |
| Jun 30, 2024 | -11.17% |
| Mar 31, 2024 | -56.88% |
| Dec 31, 2023 | -62.15% |
| Sep 30, 2023 | -51.24% |
| Jun 30, 2023 | -49.79% |
| Mar 31, 2023 | -15.03% |
| Dec 31, 2022 | 14.88% |
| Sep 30, 2022 | -22.73% |
| Jun 30, 2022 | -27.65% |
| Mar 31, 2022 | -34.60% |
| Dec 31, 2021 | -23.24% |
| Sep 30, 2021 | 21.35% |